Day: August 14, 2020

MISSISSAUGA, Ontario, Aug. 14, 2020 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, reports results for its third quarter and year to date fiscal 2020 (Q3 and YTD) ended June 30, 2020, with an increase of 141% in sales of Quality Assessment products (QAPs™).Management DiscussionOverall, Q3 revenues were down from Q3 2019, due in part to negative pressure on antigen demand for non-COVID infectious disease testing. Specifically, lower antigen revenues were achieved from Europe and Asia, from a combination of pandemic-related patient-flow disruption impacting end-user demand, an unforeseen production issue, order periodicity, and contract pricing adjustments. While antigen sales are now being negatively impacted by the pandemic, they are expected to recover across...

Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trialReported Phase 2a interim safety and efficacy data at the European Hematology Association Annual Congress and promising clinical outcomes in an Open Label Extension Study that tests IMR-687 for longer durationIMR-687 granted Orphan Drug, Fast Track and Rare Pediatric designationsby the FDA for beta-thalassemiaCompany to host conference call and live webcast today at 8:30 a.m. ETBOSTON, Aug. 14, 2020 (GLOBE NEWSWIRE) — Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today reported financial results for the second...

CHARLOTTE, N.C., Aug. 14, 2020 (GLOBE NEWSWIRE) — LPL Financial LLC (Nasdaq:LPLA), a leading retail investment advisory firm, independent broker-dealer and registered investment advisor (RIA) custodian, today announced that Andy Kalbaugh, managing director and divisional president, National Sales and Consulting, will retire at the end of the first quarter of 2021. The firm will conduct an external search to identify a new senior leader to join its management team. “We’ve been fortunate to have Andy as a leader at LPL for more than a decade, during which time he has created immeasurable value for our firm, for our advisors’ practices, and for the financial institutions we support,” said Dan Arnold, president and CEO, LPL Financial. “We’ll use the next several months to conduct a thoughtful search for a new senior leader, and Andy...

TORONTO, Aug. 14, 2020 (GLOBE NEWSWIRE) — Personas Social Incorporated (TSX.V: PRSN) (OTCQB: PKSLF) (the “Company”) announces that the audited consolidated financial statements (“Financial Statements”) and Management’s Discussion and Analysis (“MD&A”) for the year ended February 29, 2020 (“FY2020”), are now available on the Company’s profile on SEDAR (www.sedar.com).Select financial highlights from the Financial Statements include the following:The Personas Social platform generated gross revenue of $2.88 million during the FY2020 while gross margin had improved to 40% from 24% in fiscal year ended February 28, 2019GAAP net loss decreased to $4.4 million in FY2020 from $24.3 million in fiscal year ended February 28, 2019.GAAP net loss per share was $0.016 for FY2020 as compared to $0.109 for fiscal year ended February 28, 2019.Shareholders...

TORONTO, Aug. 14, 2020 (GLOBE NEWSWIRE) — Ceres Acquisition Corp. (Neo: CERE.U and CERE.WT) (“Ceres” or the “Corporation”) is reporting its financial results as of June 30, 2020 and for the period from incorporation to June 30, 2020. The Corporation’s unaudited interim financial statements, along with the accompanying management’s discussion and analysis, have been filed on the System for Electronic Document Analysis and Retrieval (SEDAR) and may be viewed by interested parties under the Corporation’s profile at www.sedar.com.About Ceres Acquisition Corp.Ceres is a newly organized special purpose acquisition corporation incorporated under the laws of the Province of British Columbia for the purpose of effecting an acquisition of one or more businesses or assets, by way of a merger, amalgamation, arrangement, share exchange, asset...

SERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application (“NDA”) submission to U.S. Food and Drug Administration (“FDA”) planned for Q1 2021Initiating the third dose cohort, 90 mcg, of the TRANQUILITY trial in elderly dementia patientsInitiated a separate efficacy cohort in the Phase 2 trial of BXCL701 in combination with pembrolizumab (“KEYTRUDA®”) to include patients with castrate-resistant prostate cancer (“CRPC”)Strengthened balance sheet through follow-on offering raising approximately $200 million in gross proceedsCompany to host conference call today at 8:30 a.m. ETNEW HAVEN, Conn., Aug. 14, 2020 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify...

NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) — Apollo Global Management, Inc. (NYSE: APO) (together with its consolidated subsidiaries, “Apollo” or the “Firm”) today announced that certain funds managed by its affiliates (“Apollo Funds”) have made a structured investment in US Wind Inc. (“US Wind”), an offshore wind energy development company. Apollo Funds have committed to invest through convertible debt and equity up to $265 million to acquire an equity stake in US Wind and fund development and construction costs associated with a major offshore wind energy project off the coast of Maryland.Baltimore, Maryland-based US Wind controls the Maryland Wind Energy Area under a Bureau of Ocean Energy Management (“BOEM”) lease of approximately 80,000 acres located ten to thirty miles off the state’s coast, an area that is sufficient to install...

Phoenix, AZ, Aug. 14, 2020 (GLOBE NEWSWIRE) — InnSuites Hospitality Trust (NYSE American: IHT) InnSuites Hospitality Trust (IHT) reported total revenues of $6.57 million from continuing operations for the fiscal year ended January 31, 2020 (FY 2020) compared to total revenues from continuing operations of $6.17 million for the fiscal year ended January 31, 2019 (FY2019), an increase of $0.4 million, or 6.5%.Consolidated Net Loss for FY2020 was approximately $2.0 million compared to Consolidated Net Income of $11.1 million for FY2019. Fiscal year ended January 31, 2019 included net income from discontinued operations of $13.1 million as a result of the profitable sales of our Yuma hotel property and our IBC technology subsidiary. We did not sell any of our properties during the fiscal year ended January 31, 2020.FY 2020 consolidated...

LAS VEGAS, Aug. 14, 2020 (GLOBE NEWSWIRE) — Marathon Patent Group, Inc. (NASDAQ:MARA) (“Marathon” or “Company”), a Nasdaq-listed cryptocurrency mining company, today announced that it has entered into a Long Term Purchase Contract with Bitmain for the purchase of 10,500 next generation Antminer S-19 Pro ASIC Miners.Marathon’s Chief Executive Officer, Merrick Okamoto, stated, “The execution of this contract with Bitmain represents a milestone event for our company. This investment is expected to result in Marathon being one of, if not the largest, Bitcoin miner in North America.”Okamoto continued, “Today’s news comes on the heels of recent incremental business growth through the purchase of what now is expected to total 13,520 next generation miners generating 1.55 Exahash upon full installation. I would like...

1% of oral dose for 30-fold lung exposure and reduced cardiotoxicityA cost-effective, easily accessible, user-friendly potential treatment/prevention optionSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 14, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced the submission of an Investigational New Drug (IND) Application to the Taiwan Food and Drug Administration (TFDA) for TLC19 Hydroxychloroquine Liposome Inhalation Suspension for the treatment of coronavirus disease 2019 (COVID-19).Is hydroxychloroquine (HCQ) still a viable drug in the prevention and treatment of COVID-19? Studies by X. Yao et al and S. Perinel et al suggest that HCQ can prevent the acidification of intracellular organelles,...